• ALL YEARS
• 2024
• 2023
• 2022

• 10/15/2024 - 18:00

  First-half 2024 results & creation of a US scientific advisory board

• 07/16/2024 - 18:00

  First-half 2024 sales

• 04/16/2024 - 18:00

  2023 annual results

• 01/23/2024 - 18:00

  2023 sales up +120% to €5.4 million

• 11/21/2023 - 18:00

  Success of a new educational program in the United States

• 11/09/2023 - 17:45

  2024 Financial calendar

• 10/18/2023 - 18:00

  First-half 2023 results

• 07/18/2023 - 17:45

  First-half 2023 sales up +203% to €4.0 million

• 06/29/2023 - 18:00

  SMAIO obtains €2.5m in non-dilutive financing

• 06/08/2023 - 07:00

  SMAIO receives FDA 510(k) clearance for customized surgery planning software co-developed with NuVasive

• 04/11/2023 - 18:00

  2022 full-year results

• 01/17/2023 - 18:00

  2022 annual sales up +15% to €2.4 million

• 01/12/2023 - 17:45

  2023 financial calendar

• 11/17/2022 - 18:00

  SMAIO: success of the first educational program in the United States, the world’s largest spine market

• 10/25/2022 - 18:00

  SMAIO announces the success of its first European educational programs

• 09/27/2022 - 18:00

  First-half 2022 results

• 07/12/2022 - 18:00

  First-half 2022 sales up +28% to €1.3 million

• 06/15/2022 - 18:00

  SMAIO receives FDA 510(k) clearance for “K-rod”, its patient-specific union rod

• 06/08/2022 - 18:00

  TP ICAP Midcap initiates coverage of SMAIO with a “Buy” recommendation

• 06/02/2022 - 18:00

  SMAIO receives FDA 510(k) clearance for its Balance Analyzer 3D surgery planning software

• 04/29/2022 - 18:00

  SMAIO, pioneer of a holistic approach to spinal surgery, announces its 2021 annual results and confirms its 2022 outlook

• 04/01/2022 - 18:00

  Success of its IPO

• 03/23/2022 - 21:00

  Launching of its IPO on the Euronext Growth® market in Paris